Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of General Psychiatry
Published in: Annals of General Psychiatry 1/2020

01-12-2020 | Schizophrenia | Primary research

Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia

Authors: Anna Michalczyk, Justyna Pełka-Wysiecka, Jolanta Kucharska-Mazur, Michał Wroński, Błażej Misiak, Jerzy Samochowiec

Published in: Annals of General Psychiatry | Issue 1/2020

Login to get access

Abstract

Background

The clinical course of schizophrenia varies among patients and is difficult to predict. Some patient populations present persistent negative symptoms, referred to as the deficit syndrome. Compared to relatives of non-deficit schizophrenia patients, family members of this patient population are at an increased risk of developing schizophrenia. Therefore, the aim of this study was to search for genetic underpinnings of the deficit syndrome in schizophrenia.

Methods

Three SNPs, i.e., rs1799732 and rs6276 located within DRD2, and rs1800497 within ANKK1, were identified in the DNA samples of 198 schizophrenia probands, including 103 patients with deficit (DS) and 95 patients with non-deficit schizophrenia (NDS). Results: No significant differences concerning any of the analyzed polymorphisms were found between DS and NDS patients. However, significant links were observed between family history of schizophrenia and the deficit syndrome, G/G genotype and rs6276 G allele. In a separate analysis, we identified significant differences in frequencies of rs6276 G allele between DS and NDS patients with family history of schizophrenia. No significant associations were found between DRD2 and ANKK1 SNPs and the age of onset or schizophrenia symptom severity.

Conclusions

The results of our preliminary study fail to provide evidence of associations between DRD2 and ANKK1 polymorphisms with the deficit syndrome or schizophrenia symptom severity, but suggest potential links between rs6276 in DRD2 and the deficit syndrome in patients with hereditary susceptibility to schizophrenia. However, further studies are necessary to confirm this observation.
Literature
1.
Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990 horizontal line 2013: a systematic literature review. BMC Psychiatry. 2015;15:193.PubMedPubMedCentralCrossRef
2.
Raballo A, Mechelli A, Menculini G, Tortorella A. Risk syndromes in psychiatry: a state-of-the-art overview. Arch Psychiatry Psychother. 2019;2:7–14.CrossRef
3.
Šumskiene EP, Donata KV. Biomedical and psychosocial interventions in the mental health care system in Lithuania: “Leaving the psychiatrist’s clinic—with at least a couple of prescriptions”. Arch Psychiatry Psychother. 2018;1:67–75.CrossRef
4.
Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–83.PubMedCrossRef
5.
Keller WR, Fischer BA, Carpenter WT Jr. Revisiting the diagnosis of schizophrenia: where have we been and where are we going? CNS Neurosci Ther. 2011;17(2):83–8.PubMedCrossRef
6.
Tandon R. The nosology of schizophrenia: toward DSM-5 and ICD-11. Psychiatr Clin North Am. 2012;35(3):557–69.PubMedCrossRef
7.
Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry. 1994;151(3):351–6.PubMedCrossRef
8.
Tek C, Kirkpatrick B, Buchanan RW. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res. 2001;49(3):253–60.PubMedCrossRef
9.
Strauss GP, Harrow M, Grossman LS, Rosen C. Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophr Bull. 2010;36(4):788–99.PubMedCrossRef
10.
Arango C, Bobes J, Kirkpatrick B, Garcia-Garcia M, Rejas J. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. Eur Neuropsychopharmacol. 2011;21(12):867–75.PubMedCrossRef
11.
Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58(2):165–71.PubMedCrossRef
12.
Shih RA, Belmonte PL, Zandi PP. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry. 2004;16(4):260–83.PubMedCrossRef
13.
Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60(12):1187–92.PubMedCrossRef
14.
Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004;18(4):251–67.PubMedCrossRef
15.
Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79–104.PubMedCrossRef
16.
Stelzel C, Basten U, Montag C, Reuter M, Fiebach CJ. Frontostriatal involvement in task switching depends on genetic differences in d2 receptor density. J Neurosci. 2010;30(42):14205–12.PubMedPubMedCentralCrossRef
17.
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000;97(14):8104–9.PubMedCrossRefPubMedCentral
18.
Schooler NR. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand Suppl. 1994;380:21–6.PubMedCrossRef
19.
Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res. 2006;85(1–3):222–31.PubMedCrossRef
20.
Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry. 2006;163(3):488–93.PubMedCrossRef
21.
Mas S, Gasso P, de Bobadilla R, Arnaiz JA, Bernardo M, Lafuente A. Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. Hum Psychopharmacol. 2013;28(6):586–93.PubMedCrossRef
22.
Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of Negative Symptoms in Schizophrenia: meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2015;41(4):892–9.PubMedCrossRef
23.
de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157(6):1019–20.PubMedCrossRef
24.
de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160(2):303–9.PubMedCrossRef
25.
Fervaha G, Caravaggio F, Mamo DC, Mulsant BH, Pollock BG, Nakajima S, et al. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study. Psychopharmacology. 2016;233(21–22):3803–13.PubMedPubMedCentralCrossRef
26.
Brito-Melo GE, Nicolato R, de Oliveira AC, Menezes GB, Lelis FJ, Avelar RS, et al. Increase in dopaminergic, but not serotoninergic, receptors in T-cells as a marker for schizophrenia severity. J Psychiatr Res. 2012;46(6):738–42.PubMedCrossRef
27.
Liu L, Luo Y, Zhang G, Jin C, Zhou Z, Cheng Z, et al. Correlation of DRD2 mRNA expression levels with deficit syndrome severity in chronic schizophrenia patients receiving clozapine treatment. Oncotarget. 2017;8(49):86515–26.PubMedPubMedCentralCrossRef
28.
Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003;73(1):34–48.PubMedPubMedCentralCrossRef
29.
Yao J, Pan YQ, Ding M, Pang H, Wang BJ. Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015;168b(1):1–13.PubMedCrossRef
30.
Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry. 1999;4(3):290–6.PubMedCrossRef
31.
Ohara K, Nagai M, Tani K, Nakamura Y, Ino A. Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry Res. 1998;81(2):117–23.PubMedCrossRef
32.
Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet. 1997;6(4):577–82.PubMedCrossRef
33.
Cordeiro Q, Siqueira-Roberto J, Zung S, Vallada H. Association between the DRD2-141C Insertion/Deletion polymorphism and schizophrenia. Arq Neuropsiquiatr. 2009;67(2a):191–4.PubMedCrossRef
34.
Saiz PA, Garcia-Portilla MP, Arango C, Morales B, Arias B, Corcoran P, et al. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: data from an association study. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):26–31.PubMedCrossRef
35.
Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P, et al. 141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. Psychiatr Genet. 2008;18(3):122–7.PubMedCrossRef
36.
He H, Wu H, Yang L, Gao F, Fan Y, Feng J, et al. Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis. Neuropsychiatr Dis Treat. 2016;12:3129–44.PubMedPubMedCentralCrossRef
37.
Wang Y, Liu L, Xin L, Fan D, Ding N, Hu Y, et al. The -141C Ins/Del and Taq1A polymorphism in the dopamine D2 receptor gene may confer susceptibility to schizophrenia in Asian populations. J Clin Neurosci. 2016;30:1–7.PubMedCrossRef
38.
Kurt H, Dikmen M, Basaran A, Yenilmez C, Ozdemir F, Degirmenci I, et al. Dopamine D2 receptor gene -141C Insertion/Deletion polymorphism in Turkish schizophrenic patients. Mol Biol Rep. 2011;38(2):1407–11.PubMedCrossRef
39.
Zhang XC, Ding M, Adnan A, Liu Y, Liu YP, Xing JX, et al. No association between polymorphisms in the promoter region of dopamine receptor D2 gene and schizophrenia in the northern Chinese Han population: a case–control study. Brain Behav. 2019;9(2):e01193.PubMedPubMedCentralCrossRef
40.
Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J. Association analysis between two functional dopamine D2 receptor gene polymorphisms and schizophrenia. Am J Med Genet. 2001;105(2):176–8.PubMedCrossRef
41.
Himei A, Koh J, Sakai J, Inada Y, Akabame K, Yoneda H. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms. Psychiatry Clin Neurosci. 2002;56(1):97–102.PubMedCrossRef
42.
Lencer R, Bishop JR, Harris MS, Reilly JL, Patel S, Kittles R, et al. Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci. 2014;264(4):345–55.PubMedCrossRef
43.
Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 2006;163(3):529–31.PubMedCrossRef
44.
Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167(7):763–72.PubMedPubMedCentralCrossRef
45.
Lencz T, Robinson DG, Napolitano B, Sevy S, Kane JM, Goldman D, et al. DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics. 2010;20(9):569–72.PubMedPubMedCentralCrossRef
46.
Nakazono Y, Abe H, Murakami H, Koyabu N, Isaka Y, Nemoto Y, et al. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients. Int J Clin Pharmacol Ther. 2005;43(4):163–71.PubMedCrossRef
47.
Tsuchimine S, Yasui-Furukori N, Sasaki K, Kaneda A, Sugawara N, Yoshida S, et al. Association between the dopamine D2 receptor (DRD2) polymorphism and the personality traits of healthy Japanese participants. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(2):190–3.PubMedCrossRef
48.
Jonsson EG, Cichon S, Gustavsson JP, Grunhage F, Forslund K, Mattila-Evenden M, et al. Association between a promoter dopamine D2 receptor gene variant and the personality trait detachment. Biol Psychiatry. 2003;53(7):577–84.PubMedCrossRef
49.
Zhang XR, Zhang ZJ, Zhu RX, Yuan YG, Jenkins TA, Reynolds GP. Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics. 2011;12(8):1127–36.PubMedCrossRef
50.
Suda A, Kawanishi C, Kishida I, Sato R, Yamada T, Nakagawa M, et al. Dopamine D2 receptor gene polymorphisms are associated with suicide attempt in the Japanese population. Neuropsychobiology. 2009;59(2):130–4.PubMedCrossRef
51.
Johann M, Putzhammer A, Eichhammer P, Wodarz N. Association of the -141C Del variant of the dopamine D2 receptor (DRD2) with positive family history and suicidality in German alcoholics. Am J Med Genet B Neuropsychiatr Genet. 2005;132(1):46–9.CrossRef
52.
Konishi T, Luo HR, Calvillo M, Mayo MS, Lin KM, Wan YJ. ADH1B*1, ADH1C*2, DRD2 (-141C Ins), and 5-HTTLPR are associated with alcoholism in Mexican American men living in Los Angeles. Alcohol Clin Exp Res. 2004;28(8):1145–52.PubMedCrossRef
53.
54.
Zhang S, Zhang M, Zhang J. An exploratory study on DRD2 and creative potential. Creat Res J. 2014;26(1):115–23.CrossRef
55.
van Munster BC, de Rooij S, Yazdanpanah M, Tienari PJ, Pitkala KH, Osse RJ, et al. The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2010;153b(2):648–55.PubMedCrossRef
56.
Lucht M, Barnow S, Schroeder W, Grabe HJ, Rosskopf D, Brummer C, et al. Alcohol consumption is associated with an interaction between DRD2 exon 8 A/A genotype and self-directedness in males. Neuropsychobiology. 2007;56(1):24–31.PubMedCrossRef
57.
Qadri YJ, Bortsov AV, Orrey DC, Swor RA, Peak DA, Jones JS, et al. Genetic polymorphisms in the dopamine receptor 2 predict acute pain severity after motor vehicle collision. Clin J Pain. 2015;31(9):768–75.PubMedPubMedCentral
58.
Crocco P, Montesanto A, Passarino G, Rose G. Polymorphisms falling within putative miRNA target sites in the 3′UTR region of SIRT2 and DRD2 genes are correlated with human longevity. J Gerontol A Biol Sci Med Sci. 2016;71(5):586–92.PubMedCrossRef
59.
Tunbridge EM, Narajos M, Harrison CH, Beresford C, Cipriani A, Harrison PJ. Which dopamine polymorphisms are functional? systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1-5, MAOA, MAOB, TH, VMAT1, and VMAT2. Biol Psychiatry. 2019;86(8):608–20.PubMedCrossRef
60.
Cordeiro Q, Vallada H. Association study between the Taq1A (rs1800497) polymorphism and schizophrenia in a Brazilian sample. Arq Neuropsiquiatr. 2014;72(8):582–6.PubMedCrossRef
61.
Dubertret C, Bardel C, Ramoz N, Martin PM, Deybach JC, Ades J, et al. A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):492–9.PubMedCrossRef
62.
Arab AH, Elhawary NA. Association between ANKK1 (rs1800497) and LTA (rs909253) Genetic Variants and Risk of Schizophrenia. Biomed Res Int. 2015;2015:821827.PubMedPubMedCentralCrossRef
63.
Aslan S, Karaoguz MY, Eser HY, Karaer DK, Taner E. Comparison of DRD2 rs1800497 (TaqIA) polymorphism between schizophrenic patients and healthy controls: lack of association in a Turkish sample. Int J Psychiatry Clin Pract. 2010;14(4):257–61.PubMedCrossRef
64.
Zhang C, Zhang J, Fan J, Cheng W, Du Y, Yu S, et al. Identification of ANKK1 rs1800497 variant in schizophrenia: new data and meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2014;165(7):564–71.CrossRef
65.
Muller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2012;12(2):156–64.PubMedCrossRef
66.
Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 2008;9(10):1437–43.PubMedCrossRef
67.
Zou YF, Wang F, Feng XL, Li WF, Tian YH, Tao JH, et al. Association of DRD2 gene polymorphisms with mood disorders: a meta-analysis. J Affect Disord. 2012;136(3):229–37.PubMedCrossRef
68.
Zhang L, Hu L, Li X, Zhang J, Chen B. The DRD2 rs1800497 polymorphism increase the risk of mood disorder: evidence from an update meta-analysis. J Affect Disord. 2014;158:71–7.PubMedCrossRef
69.
Takeuchi H, Tomita H, Taki Y, Kikuchi Y, Ono C, Yu Z, et al. The associations among the dopamine D2 receptor Taq1, emotional intelligence, creative potential measured by divergent thinking, and motivational state and these associations’ sex differences. Front Psychol. 2015;6:912.PubMedPubMedCentralCrossRef
70.
Kang SG, Na KS, Lee HJ, Chee IS, Lee K, Lee J. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks’ amisulpride treatment. J Clin Psychopharmacol. 2015;35(2):158–62.PubMedCrossRef
71.
WHO. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic criteria for research. Geneva: World Health Organization; 1993.
72.
Pużyński S, Wciórka J. Klasyfikacja zaburzeń psychicznych i zaburzeń zachowania w ICD-10. Badawcze kryteria diagnostyczne. Kraków: Vesalius; 2000.
73.
Gaebel W, Kerst A. ICD-11 Mental, behavioural or neurodevelopmental disorders: innovations and managing implementation. Arch Psychiatry Psychother. 2019;3:7–12.CrossRef
74.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33 (quiz 4-57).PubMed
75.
McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764–70.PubMedCrossRef
76.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.PubMedCrossRef
77.
Rzewuska M. Badanie zgodności i niezawodności polskiej wersji skali PANSS [Examination of compliance and reliability of the Polish version of the PANSS scale]. Farmakoterapia w Psychiatrii i Neurologii. 2004;4:390–8.
78.
79.
Obermeier M, Mayr A, Schennach-Wolff R, Seemuller F, Moller HJ, Riedel M. Should the PANSS be rescaled? Schizophr Bull. 2010;36(3):455–60.PubMedCrossRef
80.
Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;416:16–23.CrossRef
81.
Pełka-Wysiecka J. [Genetic and physiologic markers of negative symptoms in schizophrenia: a search for the biologically founded deficit phenotype of the disease]. In: Kojder I, editor. Annales Academiae Medicae Stetinensis. supplement 175. Szczecin: Pomeranian Medical University in Szczecin; 2013.
82.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedCrossRef
83.
Stańczak J. MMSE - polska normalizacja [MMSE - polish normalization]. Psychological Test Laboratory of Polish Psychological Association; 2010.
84.
Jarema M, Kiejna A, Landowski J, Meder J, Jolanta RJ, Rybakowski J. Pharmacological standards in schizophrenia treatment. Psychiatr Pol. 2006;40(6):1171–205.PubMed
85.
Tybura P, Samochowiec A, Beszlej A, Grzywacz A, Mak M, Frydecka D, et al. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients. Pharmacol Rep. 2012;64(3):528–35.PubMedCrossRef
86.
Jaracz J, Tetera-Rudnicka E, Kujath D, Raczynska A, Stoszek S, Czernas W, et al. The prevalence of antipsychotic polypharmacy in schizophrenic patients discharged from psychiatric units in Poland. Pharmacol Rep. 2014;66(4):613–7.PubMedCrossRef
87.
Jarema M, Wichniak A, Dudek D, Samochowiec J, Bienkowski P, Rybakowski J. Guidelines for the use of second-generation long-acting antipsychotics. Psychiatr Pol. 2015;49(2):225–41.PubMedCrossRef
88.
Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30(2):119–23.PubMedCrossRef
89.
Pelka-Wysiecka J, Wronski M, Jasiewicz A, Grzywacz A, Tybura P, Kucharska-Mazur J, et al. BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. Pharmacol Rep. 2013;65(5):1185–93.PubMedCrossRef
90.
Pelka-Wysiecka J, Wronski M, Bienkowski P, Murawiec S, Samochowiec A, Samochowiec J. Odors identification differences in deficit and nondeficit schizophrenia. Pharmacol Rep. 2016;68(2):390–5.PubMedCrossRef
91.
Tyburski E, Pelka-Wysiecka J, Mak M, Samochowiec A, Bienkowski P, Samochowiec J. Neuropsychological Profile of Specific Executive Dysfunctions in Patients with Deficit and Non-deficit Schizophrenia. Front Psychol. 2017;8:1459.PubMedPubMedCentralCrossRef
92.
Bienkowski P, Samochowiec J, Pelka-Wysiecka J, Grzywacz A, Skibinska M, Jasiewicz A, et al. Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype. Pharmacol Rep. 2015;67(3):442–5.PubMedCrossRef
93.
94.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed: Lawrence Erlbaum Associates; 1988.
95.
Gurling HMD, McQuillin A. The genetics of schizophrenia. In: Nurnberger JJ, Berrettini W, editors. Principles of Psychiatric Genetics. Cambridge: Cambridge University Press; 2012. p. 230–61.CrossRef
96.
Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40(7):827–34.PubMedCrossRef
97.
98.
Glatt SJ, Faraone SV, Tsuang MT. DRD2 -141C insertion/deletion polymorphism is not associated with schizophrenia: results of a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2004;128b(1):21–3.PubMedCrossRef
99.
Edwards AC, Bacanu SA, Bigdeli TB, Moscati A, Kendler KS. Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study. Schizophr Res. 2016;176(2–3):136–40.PubMedPubMedCentralCrossRef
100.
Dollfus S, Ribeyre JM, Petit M. Family history and deficit form in schizophrenia. Eur Psychiatry. 1996;11(5):260–2.PubMedCrossRef
101.
Ross DE, Kirkpatrick B, Karkowski LM, Straub RE, MacLean CJ, O’Neill FA, et al. Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am J Psychiatry. 2000;157(7):1071–6.PubMedCrossRef
102.
Chien YL, Hwu HG, Fann CS, Chang CC, Tsuang MT, Liu CM. DRD2 haplotype associated with negative symptoms and sustained attention deficits in Han Chinese with schizophrenia in Taiwan. J Hum Genet. 2013;58(4):229–32.PubMedCrossRef
103.
Wang YM. A commentary on DRD2 haplotype associated with negative symptoms and sustained attention deficits in Han Chinese with schizophrenia in Taiwan. J Hum Genet. 2013;58(4):182.PubMedCrossRef
Metadata
Title
Association between DRD2 and ANKK1 polymorphisms with the deficit syndrome in schizophrenia
Authors
Anna Michalczyk
Justyna Pełka-Wysiecka
Jolanta Kucharska-Mazur
Michał Wroński
Błażej Misiak
Jerzy Samochowiec
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Schizophrenia
Published in
Annals of General Psychiatry / Issue 1/2020
Electronic ISSN: 1744-859X
DOI
https://doi.org/10.1186/s12991-020-00289-0

Other articles of this Issue 1/2020

Annals of General Psychiatry 1/2020 Go to the issue

Primary research

Dietary habits and psychological disorders in a large sample of Iranian adults: a population-based study

Review

MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t

Primary research

Aggressive behavior and metacognitive functions: a longitudinal study on patients with mental disorders

Primary research

Recording of cardiovascular risk factors by general practitioners in patients with schizophrenia

Case report

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report

Primary research

The association of intimate partner violence with postpartum depression in women during their first month period of giving delivery in health centers at Dessie town, 2019